Recombinant Human Antibody (b70) is capable of binding to Protein jagged-1, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-Protein jagged-1 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-Protein jagged-1 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Figure 1 Immunoblot analysis of NOTCH2 intracellular domain (NICD2) in U87 glioblastoma cells to assess selectivity of JAG1 inhibition.
Anti-JAG1.b70 (25 μg/ ml) completely blocked NOTCH2 signalling.
Lafkas, D., Shelton, A., Chiu, C., de Leon Boenig, G., Chen, Y., Stawicki, S. S., ... & Eastham-Anderson, J. (2015). Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature, 528(7580), 127-131.
Figure 2 Immunofluorescence staining of bronchiolar epithelium for CC10 (green) and FOXJ1 (red) from mice dosed every 3 days over 8 days with the anti-JAG1.b70 antibody.
Nuclei were counterstained with DAPI.
Lafkas, D., Shelton, A., Chiu, C., de Leon Boenig, G., Chen, Y., Stawicki, S. S., ... & Eastham-Anderson, J. (2015). Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature, 528(7580), 127-131.
Figure 3 Haematoxylin and eosin staining of skin from mice treated with anti-JAG1.b70.
JAG2 but not JAG1 inhibition induced a loss of mature sebocytes in sebaceous glands.
Lafkas, D., Shelton, A., Chiu, C., de Leon Boenig, G., Chen, Y., Stawicki, S. S., ... & Eastham-Anderson, J. (2015). Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature, 528(7580), 127-131.
Figure 4 Representative immunofluorescence images (BrdU, green) of sections used for the quantification.
Percentages of BrdU-positive airway cells (n = 5 mice per group).
Lafkas, D., Shelton, A., Chiu, C., de Leon Boenig, G., Chen, Y., Stawicki, S. S., ... & Eastham-Anderson, J. (2015). Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature, 528(7580), 127-131.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-617 | Human Anti-JAG1 Recombinant Antibody; Fab Fragment | WB, ELISA, FuncS | Human Fab |
NS-049CN-F(E) | Human Anti-JAG1 Recombinant Antibody; Fab Fragment (NS-049CN-F(E)) | ELISA, WB, IF | Human Fab |
HPAB-0947LY-F(E) | Human Anti-JAG1 Recombinant Antibody; Fab Fragment (HPAB-0947LY-F(E)) | ELISA | Human Fab |
HPAB-0948LY-F(E) | Human Anti-JAG1 Recombinant Antibody; Fab Fragment (HPAB-0948LY-F(E)) | ELISA | Human Fab |
HPAB-0949LY-F(E) | Human Anti-JAG1 Recombinant Antibody; Fab Fragment (HPAB-0949LY-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0602CL | Mouse Anti-JAG1 Recombinant Antibody (TAB-0602CL) | FC, DB | Mouse IgG |
TAB-0603CL | Mouse Anti-JAG1 Recombinant Antibody (TAB-0603CL) | Block, DB, ELISA | Mouse IgG |
TAB-0604CL | Human Anti-JAG1 Recombinant Antibody (TAB-0604CL) | ELISA | Human antibody |
TAB-0605CL | Human Anti-JAG1 Recombinant Antibody (TAB-0605CL) | ELISA | Human antibody |
PABX-126-S (P) | Recombinant Human Anti-Jag1 Antibody scFv Fragment (JAG2.b33) | WB, Neut, FuncS | scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PABX-126-F (E) | Recombinant Human Anti-Jag1 Antibody Fab Fragment (JAG2.b33) | WB, Neut, FuncS | Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1607CQ | Recombinant Mouse Anti-JAG1 Antibody (CBL125) | FC, WB, Neut | IgG2 |
NEUT-1608CQ | Recombinant Mouse Anti-JAG1 Antibody (4A24) | FC, Neut | IgG2 |
NEUT-1609CQ | Recombinant Mouse Anti-JAG1 Antibody (CBL581) | Neut | IgG2b |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1895 | Hi-Affi™ Recombinant Rabbit Anti-JAG1 Monoclonal Antibody (DS1895AB) | WB, IHC-P, ICC/IF | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
NS-049CN | Human Anti-JAG1 Recombinant Antibody (NS-049CN) | ELISA, WB, IF | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1018LY-S(P) | Human Anti-JAG1 Recombinant Antibody; scFv Fragment (HPAB-1018LY-S(P)) | ELISA | Human scfv |
HPAB-1019LY-S(P) | Human Anti-JAG1 Recombinant Antibody; scFv Fragment (HPAB-1019LY-S(P)) | ELISA | Human scfv |
HPAB-1020LY-S(P) | Human Anti-JAG1 Recombinant Antibody; scFv Fragment (HPAB-1020LY-S(P)) | ELISA | Human scfv |
HPAB-1021LY-S(P) | Human Anti-JAG1 Recombinant Antibody; scFv Fragment (HPAB-1021LY-S(P)) | ELISA | Human scfv |
HPAB-0474-FY-S(P) | Human Anti-JAG1 Recombinant Antibody; scFv Fragment (HPAB-0474-FY-S(P)) | ELISA | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0957LY | Human Anti-JAG1 Recombinant Antibody (HPAB-0957LY) | ELISA | Human IgG |
HPAB-0958LY | Human Anti-JAG1 Recombinant Antibody (HPAB-0958LY) | ELISA | Human IgG |
HPAB-0959LY | Human Anti-JAG1 Recombinant Antibody (HPAB-0959LY) | ELISA | Human IgG |
HPAB-0960LY | Human Anti-JAG1 Recombinant Antibody (HPAB-0960LY) | ELISA | Human IgG |
HPAB-0961LY | Human Anti-JAG1 Recombinant Antibody (HPAB-0961LY) | ELISA | Human IgG |
There are currently no Customer reviews or questions for PABL-312. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.